RxDoctor Payments Data

Nabil Aziz, MD

Neurology · Liverpool, NYNPI 1740375617

Payments from drug & device makers

$17,472in general payments, 2019–2025

Across 338 payments — averaging $51.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$7K
  • Acadia Pharmaceuticals Inc$4K
  • Biogen$957
  • AbbVie$826
  • Sanofi$366
  • Lilly USA, LLC$289
  • plus $4K from 54 others

What the payments were for

  • Consulting fees$4,99929%
  • Speaking & faculty fees$5,83533%
  • Travel & lodging$4092%
  • Food & beverage$6,12535%
  • Education$1031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.17$7,029
Acadia Pharmaceuticals Inc14$3,907
Biogen36$957
AbbVie(2 entities)56$826
Sanofi12$366
Lilly USA, LLC11$289
Amneal Pharmaceuticals LLC12$241
Novartis8$217
Genentech USA, Inc.11$195
TG Therapeutics, Inc.5$176
Neurocrine Biosciences, Inc.8$173
MDD US Operations, LLC7$170
UCB, Inc.6$168
Lundbeck LLC8$167
SK Life Science, Inc.8$162
Livanova USA, Inc.4$158
EMD Serono, Inc.9$155
AstraZeneca8$154
Pfizer7$138
Acorda Therapeutics, Inc6$120
Mallinckrodt Hospital Products Inc.2$113
Eisai Inc.5$112
Bristol Myers Squibb5$108
Sunovion Pharmaceuticals Inc.6$93
Jazz Pharmaceuticals Inc.4$78
Neurelis, Inc.2$73
Catalyst Pharmaceuticals, Inc.3$69
CSL Behring3$64
Upsher-smith Laboratories LLC3$62
Abbott3$59
Boston Scientific1$55
Amgen3$48
Sumitomo Pharma America, Inc.3$48
Octapharma USA, Inc.2$46
Argenx US, Inc.2$39
Alnylam Pharmaceuticals Inc.2$38
Impel Pharmaceuticals Inc.2$36
Merz Pharmaceuticals, LLC2$33
Adamas Pharmaceuticals, Inc.2$33
Esperion Therapeutics, Inc.2$33
Kyowa Kirin, Inc.2$32
Biohaven Pharmaceuticals, Inc.2$31
Supernus Pharmaceuticals, Inc.2$31
Johnson & Johnson1$31
Avanir Pharmaceuticals, Inc.2$29
Assertio Therapeutics, Inc.2$28
Collegium Pharmaceutical, Inc.1$24
Vanda Pharmaceuticals Inc.1$24
E.r. Squibb & Sons, L.L.C.1$23
Banner Life Sciences, LLC1$23
ANI Pharmaceuticals, Inc.1$22
Mallinckrodt Enterprises LLC1$22
Tanabe Pharma America, Inc.1$21
Arbor Pharmaceuticals, Inc.1$20
Akcea Therapeutics, Inc.1$19
Otsuka America Pharmaceutical, Inc.1$19
Grifols USA, LLC1$18
Bayer1$16
Nevro Corp.1$14
Avion Pharmaceuticals1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,472 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$185,493
Medicare patients
372
Services billed
10,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5022$383,265
NuplazidPimavanserin Tartrate26$226,505
RebifInterferon Beta-1a/Albumin11$112,686
Kesimpta PenOfatumumab12$103,146
CopaxoneGlatiramer Acetate12$68,861
Teriflunomide23$62,048
BotoxOnabotulinumtoxina29$40,328
Tegretol XrCarbamazepine15$16,221
Emgality PenGalcanezumab-Gnlm24$16,195
Dalfampridine ErDalfampridine27$14,003
Galantamine ErGalantamine Hbr142$12,742
Carbidopa-LevodopaCarbidopa/Levodopa295$12,373
Aimovig AutoinjectorErenumab-Aooe16$11,751
Lamotrigine ErLamotrigine16$9,917
Rasagiline Mesylate50$9,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$138$383,26522 claims
Acadia Pharmaceuticals IncNuplazid$3,907$226,50526 claims
EMD Serono, Inc.Rebif$155$112,68611 claims
Teva Pharmaceuticals USA, Inc.Copaxone$7,029$68,86112 claims
AbbVieBotox$826$40,32829 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$241$1,95923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →